FTC Claim Substantiation Standards, Reasonable Basis, and the Regulatory Risks of Borrowed Science

If you sit in marketing, your job is to articulate why a product matters. If you sit in legal or regulatory compliance, your job is to keep the company from receiving a civil investigative demand.

Too often, the friction between those two roles comes down to a fundamental misunderstanding of what a claim actually is—and what the Federal Trade Commission requires before that claim ever meets a consumer.

A brief disclaimer: While we analyze regulatory trends and compliance infrastructure, this analysis is informational and does not constitute formal legal advice.

What the Commission Actually Means by a "Claim"

In brand strategy, a claim is a value proposition. In the eyes of the FTC, a claim is any representation about what a product can do, how it performs, or what results a buyer can reasonably expect.

Crucially, the regulator does not evaluate claims in isolation based solely on literal phrasing. Under the long-standing FTC Policy Statement Regarding Advertising Substantiation, the Commission looks at both express claims and implied claims.

An express claim is direct: "This botanical extract reduces cortisol by 30%."

An implied claim is everything else: the imagery, the juxtaposition of text, the customer testimonials, and the overall net impression. If an advertisement depicts a doctor in a lab coat standing next to a joint health gummy while discussing clinical research, the implied claim is that the gummy itself has been clinically proven to deliver those exact therapeutic benefits—even if the voiceover never explicitly utters the words.

The Standard: Having a "Reasonable Basis"

To the FTC, the difference between an ordinary claim and a substantiated claim comes down to one requirement: having a reasonable basis before the claim is disseminated.

A substantiated claim is not a claim you believe to be true. It is not a claim backed by customer enthusiasm, five-star reviews, or internal team intuition. In the FTC's regulatory framework, substantiation requires objective evidence that directly matches the specific level of efficacy communicated to the market.

When health, safety, or functional performance claims are involved, the FTC almost universally interprets a "reasonable basis" as competent and reliable scientific evidence. In plain terms: tests, analyses, research, or studies conducted and evaluated in an objective manner by qualified experts, using procedures generally accepted in the relevant profession to yield accurate and reliable results.

If an ad states or implies that a product is "clinically proven," the substantiation must be actual clinical proof on that specific product formulation. If the ad implies general support, the evidence must still be robust enough to support that broad takeaway.

The Industry Blind Spot: "Borrowed Science"

In our experience auditing claim structures across consumer health, functional beverage, and personal care brands, the most frequent failure point is not malice. It is borrowed science.

Here is what most compliance checklists gloss over: relying on raw-material supplier whitepapers is one of the fastest ways to build an unsubstantiated product claim.

A supplier may have a sound, double-blind study showing that 500mg of an active branded peptide demonstrated statistically significant outcomes in human trials. But if your finished formulation contains 100mg blended with three other active ingredients in a different delivery matrix, that supplier study does not substantiate your finished-product claim.

You cannot claim the destination if you cut the dosage or altered the vehicle. Taking an ingredient-level study on mice and projecting it onto an OTC or dietary supplement label as a validated human outcome is not substantiation. In the Commission's framework, that claim is legally naked the moment it goes live.

The Real Cost of an Unsubstantiated Claim

The FTC has intensified its focus on claim validity through formal administrative mechanisms. Under 15 U.S.C. § 45(m)(1)(B), if a company engages in unfair or deceptive acts with actual knowledge that the Commission has already determined those acts to be unlawful in prior litigated cases, the agency can seek civil penalties of up to $50,120 per violation.

To establish that statutory "actual knowledge," the FTC began issuing targeted Notices of Penalty Offenses directly to thousands of brand executives.

Across the five published FTC Notice of Penalty Offenses recipient lists, our unified index covers 2,527 distinct companies. Exactly 50 of them appear on more than one list. The distribution spans critical commercial practices:

• Money-making opportunities: 1,131 companies
• Endorsements and testimonials: 705 companies
• Substantiation of product claims: 665 companies
• For-profit education: 70 companies
• Misuse of information collected in confidential contexts: 6 companies

It is essential to state this plainly: appearing on an FTC Notice of Penalty Offenses recipient list is not an indication or accusation that a company has done anything wrong.

Receiving a Notice simply means the Commission sent formal correspondence outlining conduct it considers unlawful across the wider market. However, receiving that notice legally strips away the defense of ignorance. For the 665 companies that received the Notice concerning product claim substantiation, the threshold for future administrative enforcement became substantially higher overnight.

Building Defensible Claims

Substantiation is not a legal defense drafted after receiving an inquiry letter. It is an operational asset assembled before the marketing calendar begins.

Before signing off on customer-facing copy, ask three foundational questions:

1. What is the net impression? Step back from the technical wording. What does a tired, hurried consumer assume this product will do within ten seconds of scanning the page?
2. Does the evidence match the exact claim? If you claim rapid absorption, do you have pharmacokinetic data verifying that speed, or simply data showing eventual bioavailability?
3. Did we have the documentation prior to launch? Substantiation cannot be retrofitted. Evidence generated after a claim has circulated does not cure the regulatory defect of making an unsubstantiated claim at the time of publication.

If your organization manufactures or markets consumer products, knowing your regulatory baseline is critical. The FTC published these recipient rosters across five separate, disconnected PDF files, making it cumbersome for operational teams to cross-reference their standing. We consolidated all five into a single, unified database covering all 2,527 distinct entities. You can run your company name through our free searchable index in a few seconds to verify your position.

---